ATE473004T1 - Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren - Google Patents

Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren

Info

Publication number
ATE473004T1
ATE473004T1 AT07755283T AT07755283T ATE473004T1 AT E473004 T1 ATE473004 T1 AT E473004T1 AT 07755283 T AT07755283 T AT 07755283T AT 07755283 T AT07755283 T AT 07755283T AT E473004 T1 ATE473004 T1 AT E473004T1
Authority
AT
Austria
Prior art keywords
cholecystokinin
substituted imidazole
carboxamide
receptor modulators
receptor
Prior art date
Application number
AT07755283T
Other languages
English (en)
Inventor
Joseph Duffy
Scott Edmondson
Alexa Hansen
Cheng Zhu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE473004T1 publication Critical patent/ATE473004T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
AT07755283T 2006-04-14 2007-04-10 Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren ATE473004T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79213406P 2006-04-14 2006-04-14
PCT/US2007/008956 WO2007120718A2 (en) 2006-04-14 2007-04-10 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators

Publications (1)

Publication Number Publication Date
ATE473004T1 true ATE473004T1 (de) 2010-07-15

Family

ID=38610151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07755283T ATE473004T1 (de) 2006-04-14 2007-04-10 Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren

Country Status (8)

Country Link
US (1) US7759352B2 (de)
EP (1) EP2010179B1 (de)
JP (1) JP2009533449A (de)
AT (1) ATE473004T1 (de)
AU (1) AU2007238744A1 (de)
CA (1) CA2650401A1 (de)
DE (1) DE602007007594D1 (de)
WO (1) WO2007120718A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008144962A (ru) 2006-04-14 2010-05-20 Мерк энд Ко., Инк. (US) Замещенные имидазол-4-карбоксамиды в качестве модуляторов рецепторов холецистокина-1
CA2649927A1 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
WO2009001915A1 (ja) * 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
JP2004520346A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ受容体発現のインデューサーとしてのアリールピペリジン誘導体
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US7109216B2 (en) 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
UY27450A1 (es) * 2001-09-24 2003-04-30 Bayer Corp Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
US20040248956A1 (en) 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
WO2004094407A1 (ja) 2003-04-21 2004-11-04 Daiichi Pharmaceutical Co. Ltd. ５員複素環誘導体
US20050026983A1 (en) 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
KR20060117952A (ko) 2003-10-20 2006-11-17 솔베이 파마슈티칼스 비. 브이 카나비노이드 수용체 조절제로서 1ｈ-이미다졸 유도체
US20050124660A1 (en) 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
WO2005063716A1 (en) 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
US7799804B2 (en) 2004-04-03 2010-09-21 Astrazeneca Ab Therapeutic agents
RU2008144962A (ru) 2006-04-14 2010-05-20 Мерк энд Ко., Инк. (US) Замещенные имидазол-4-карбоксамиды в качестве модуляторов рецепторов холецистокина-1
CA2649927A1 (en) 2006-04-14 2007-10-25 Merck & Co., Inc. Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators

Also Published As

Publication number Publication date
EP2010179B1 (de) 2010-07-07
JP2009533449A (ja) 2009-09-17
WO2007120718A2 (en) 2007-10-25
DE602007007594D1 (de) 2010-08-19
EP2010179A4 (de) 2009-05-06
AU2007238744A1 (en) 2007-10-25
WO2007120718A3 (en) 2008-07-24
EP2010179A2 (de) 2009-01-07
CA2650401A1 (en) 2007-10-25
US7759352B2 (en) 2010-07-20
US20090281117A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
ATE515504T1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
ATE473004T1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
ATE479435T1 (de) Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
EP2217596B8 (de) Bicyclische heterocyclische derivate und ihre verwendung als modulatoren der aktivität von gpr 119
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
TW200745126A (en) Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
EA200800835A1 (ru) Циклопропиламины в качестве модуляторов рецептора гистамина н
DE60309739D1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
IL193479A0 (en) Modulators of muscarinic receptors
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DE602007009873D1 (de) Substituierte diazepin-sulfonamide als bombesin-rezeptor-subtyp-3-modulatoren
MX2009004112A (es) Imidazoles sustituidos como moduladores del receptor de bombesina subtipo-3.
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
NO20083045L (no) Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkomplekset
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
MX2009009364A (es) Compuestos de indol y benzotiofeno como moduladores del receptor de histamina h3.
ATE528006T1 (de) Substituierte aminopyrimidine als cholecystokinin-1-rezeptormodulatoren
WO2008051404A3 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
ATE540953T1 (de) Bizyklische imidazol- oder thiadiazol- heterozyklen als selektive androgen-rezeptor- modulatoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties